the CLSI revised the clinical breakpoints for the azoles and the echinocandins against Candida species. Our objective was to evaluate what effect the new antifungal clinical breakpoints may have on antifungal susceptibility patterns in Candida species isolated from patients with candidemia in our geographic. Methods: We performed a retrospective, descriptive analysis of triazole and echinocandin MICs against Candida species obtained from blood culture in one medical center of Southern Taiwan

more »

... ween January 2007 and January 2012. Antifungal susceptibility tests were determined using the broth microdilution method with Sensititre Yeast One system. Differences in susceptibility rates between the previous and revised breakpoints were assessed for significance by Fisher's exact test and a P value of <0.05 was considered significant. Results: During the study period, 709 Candida isolates were obtained from the patients with candidemia. Isolates were classified as susceptibility based on both the previous and the recently revised CLSI clinical breakpoints. The significant reducing susceptibility in two azoles (fluconazole, voriconazole) and three echinocandins (anidulafungin, capsofungin, micafungin) against C. tropicalis, two echinocandins (anidulafungin, capsofungin) against C. glabrata and capsofungin against C. krusei were found. Conclusions: The non-susceptible rates of azoles and echinocandin against some Candida species increase with interpretation according to the revised CLSI breakpoints. Further studies are needed to confirm the clinical relevance. PS 2-363 CHANGES IN THE ENVIRONMENT CLEAN PROCESSES TO REDUCE ENVIRONMENTAL CLEAN COLONIZATION